首页|Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma

Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
AIM:To investigated whether sall3 transcription was regulated by promoter CpG island hypermethylation in hepatocellular carcinoma (HCC).METHODS:The cell lines Huh7,HepG2,SK-HEP1,SMMC7721,Bel7402,QGY7703 and a cohort of 38 HCC tissue specimens and corresponding nontumorous tissues were subjected to analysis for sall3 promoter CpG island methylation and mRNA transcription.sall3 promoter CpG island methylation levels were determined using the MassARRAY platform and mRNA transcription levels of the gene were detected by quantitative realtime polymerase chain reaction.RESULTS:The levels of sall3 mRNA were decreased by more than twofold in 33 of 38 tumor tissues compared to adjacent noncancerous tissues.Among these 33 tumor tissues with lower levels of sall3 mRNA,24 showed higher levels of methylation.Based on these results,we hypothesized that the decrease in sall3 mRNA transcription level was likely due to promoter CpG island hypermethylation.Changes in sall3 mRNA transcription and promoter CpG island methylation were determined in the above six cell lines after treatment with 0,0.1,0.5 and 2.5 μmol 5-aza-2-deoxycytidine,a demethylating agent.Promoter CpG island methylation levels decreased in a dose-dependent manner in all six cell lines,while the mRNA transcription level increased dosedependently in Huh7,HepG2,SK-HEP1 and SMMC7721 cells and irregularly in Bel7402 and QGY7703 cells.CONCLUSION:These results indicated that promoter CpG island hypermethylation contributes to the downregulation of sall3 mRNA transcription in HCC.

Hepatocellular carcinomasall3Aberrant methylationDown regulation mRNA transcription

Xue-Xi Yang、Jing-Zhe Sun、Fen-Xia Li、Ying-Song Wu、Hong-Yan Du、Wei Zhu、Xiang-Hong Li

展开 >

School of Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China

Department of VIP ward, 306th Hospital of People's Liberation Army, Beijing 100101, China

Department of Toxicology, Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, Guangdong Province, China

Department of Hepatobiliary Surgery, Nanfang Hospital, Guangzhou 510515, Guangdong Province, China

展开 >

Supported by Key Programs for Science and Technology Development of GuangzhouNational High Technology Research and Development Program of China

2008A1-E41512006AA02A311

2012

10.3748/wjg.v18.i21.2719

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子：1.001
ISSN：1007-9327
年,卷(期)：2012.18(21)
  • 3
  • 1